Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer Matt Pulisic joined the company as its new Chief Financial Officer Closing of $10.5 Million Underwritten Offering of Common Stock $30.9 million in cash, cash equivalents and short-term... Read More

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and... Read More

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at... Read More

U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for... Read More

WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial... Read More

WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at... Read More

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial, a US-based, Phase 2 trial (VIRO-25) treating patients with recurrent advanced or metastatic non-small cell lung cancer (NSCLC)... Read More

WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference, taking place November 11-13, 2024, in... Read More

VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer Trial represents second indication in the clinic for Olvi-Vec via systemic administration Interim readout expected mid-2025 WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation... Read More

WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place October 15-17, 2024. Mr. Zindrick will discuss clinical-stage programs, recent announcements, and upcoming milestones in a... Read More

WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New... Read More

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates. “The past quarter has continued to be transformative for the company as we completed a key financing expected to provide runway through three trial readouts, including our ongoing... Read More

WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2024. The conversation with Kaveri Pohlman, PhD, Director and BTIG... Read More

WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before... Read More

WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to... Read More

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates. “Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients,” said Thomas Zindrick , President, Chairman and CEO... Read More

Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer... Read More

Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company,... Read More

Expanded executive team as Lourie Zak appointed Chief Financial Officer Extended clinical focus on systemic administration in small cell lung cancer $29.9 million in cash and equivalents WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business... Read More

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company’s 2023 Inducement Plan, including an... Read More

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11 t h , 2023. The Company will also attend virtual... Read More

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023. "I am excited to welcome Lourie to Genelux as our new Chief Financial Officer," said Thomas Zindrick , President, Chairman and CEO of Genelux. "Lourie’s extensive experience... Read More

Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index Publication of VIRO-15 Phase 2 data in JAMA Oncology $51 Million raised after closing of two private placements in Q2, totaling $65 million raised in the first half of 2023 Current cash and cash commitments expected to fund operations into Q1 2026 WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:... Read More

WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023. The conversation with Kaveri Pohlman, PhD, Director and BTIG... Read More

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of two new members to its leadership team. Joseph Cappello, Ph.D ., who previously served as the Company’s Vice President of Pharmaceutical Development, has been promoted to Chief Technical Officer. Tony Yu, Ph.D.,... Read More

Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density and increase in immune cell density, confirming the mechanism of action of both direct cytotoxic and immune-activating effects.... Read More

V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral immunotherapy) and TVAX Immunotherapy ® (vaccine-enhanced adoptive T cell therapy). The patent expiry for the combination, prior to any patent term extension, will be in 2036. WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE... Read More

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.... Read More

WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, before deducting offering expenses payable by Genelux. The financing was led by existing investors and no... Read More

Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responses Generated promising progression-free survival Demonstrated clinical reversal of platinum resistance and refractoriness Phase 3 OnPrime/GOG-3076 randomized active-controlled registrational trial in collaboration with GOG Foundation/Partners is currently enrolling... Read More

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before deducting offering expenses payable by Genelux. Proceeds from the private placement, combined with the current... Read More

WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced that it will ring the Nasdaq Stock Market (“Nasdaq”) opening bell on... Read More